Autonomix Medical, Inc. · NASDAQ:AMIX
Autonomix Medical — Investor Presentation (March 2024)
23 slides from Autonomix Medical's investor presentation, Mar 4, 2024
Slide 1: Breakthrough Technology That Could Transform Nerve-Targeted Treatments
Breakthrough Technology That Could Transform Nerve - Targeted Treatments
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward - looking statements . The words “believ
Slide 3: Unleashing the Power of Nerve-Targeted Treatments
Unleashing the Power of Nerve - Targeted Treatments 3 3,000 times greater sensitivity than currently available technologies Lead program in pancreatic cancer - related pain represents compelling multi - billion - dollar opportunity Human POC clinical trial ongoing with enrollment is expected before
Slide 4: The Nervous System is Responsible for Key Bodily Functions
The Nervous System is Responsible for Key Bodily Functions 4
Slide 5: The Problem
The Problem The ability to target and treat nerves is severely limited because physicians lack the necessary tools to sense, target and influence neuronal signals safely and reliably. Essentially, making otherwise potentially effective treatments very risky. Creating an approach that’s been called “
Slide 6: Potential Applications: This Could Change Everything
POTENTIAL APPLICATIONS This could change everything. When it comes to the fields of neurophysiology and electrophysiology, we believe we can enable procedures like Medtronic’s renal denervation to advance from “treat and pray” to “sense, treat and verify,” which we believe may translate into faster,
Slide 7: Potential Applications: Pain Management
It’s almost universally accepted that the current approach to pain management is broken. In 2020, pharmacies filled 142 million opioid prescriptions. Enough for 43% of Americans to receive one. These highly addictive opioids are prescribed for all sorts of pain - From cancer pain to hip replacements
Slide 8: Compelling Opportunity
Compelling Opportunity PROBLEM OPPORTUNITY Durable Pain Relief Pancreatic tumors often cause severe pain that is very difficult to manage. We are seeking to create a minimally invasive procedure to deliver a durable and meaningful reduction in the pain of the patient. PROBLEM OPPORTUNITY Targeted Tr
Slide 9: Ongoing Proof of Concept Clinical Trial in Pain Associated with Pancreatic Cancer
Ongoing Proof of Concept Clinical Trial in Pain Associated with Pancreatic Cancer 9 Trial to Assess the Use of Transvascular RF Ablation for the Treatment of Pancreatic C ancer P ain Study Design Timelines Number of Subjects: 20 Clinical Sites 1 Objective Ablate relevant somatic nerves and mitigate
Slide 10: Proof-of-Concept in Lead Indication Opens Up a >$100 Billion Total Market Opportunity
Proof - of - Concept in Lead Indication Opens Up a >$100 Billion Total Market Opportunity 10 1. https:// www.mordorintelligence.com /industry - reports/pain - management - market 2. https:// www.polarismarketresearch.com /industry - analysis/global - hypertension - drug - market 3. https:// www.prec
Slide 11: Our Breakthrough Solution
Think of our device candidate as a GPS for the nervous system. Like the MRI, our technology may provide a significant leap forward in diagnostic abilities. Detects and differentiates signals from the nervous system throughout the body with extremely high sensitivity. Our catheter - based platform is
Slide 12: Patented Catheter Technology
Patented Catheter Technology Custom Antenna Array Our state - of - the - art custom antennae array is being designed to detect, map, display and modulate the problem accurately and safely. Guidewire & Catheter Bodies Small enough to reach any organ. Digital rendering, not final device. Proprietary C
Slide 13: Cardiac Signal Strength vs Neural Signal Strength
13 100 μ V 1 - 2 μ V Cardiac Signal Strength Neural Signal Strength
Slide 14: Our Patented Catheter Technology
Our Patented Catheter Technology We took the equivalent of bulky lab equipment and reduced it down to the size of a 1 by 2 millimeter microchip that we could then position just millimeters away from the nerves we are sensing . 14 Signal travels millimeters to be processed AUTONOMIX Stronger cardiac
Slide 15: Our Patented Catheter Technology
Replaces This (Typical Catheter Lab) Our Patented Catheter Technology Such a small form factor microchip, similar to the one used in today's Apple Watch, wasn't commercially available until recently . We not only own the exclusive patent rights to this intravascular approach, but we’ve proven it wor
Slide 16: Proprietary Catheter in Artery, Target Nerves
PROPRIETARY CATHETER IN ARTERY TARGET NERVES (SHOWN IN YELLOW) By placing our proprietary chip on the tip of the catheter, we expect to be able to sense, identify, and treat nerves with 3000x more sensitivity than alternative methods. 16
Slide 17: Developing a Disruptive Technology at the Center of the Industry
We are developing a disruptive technology at the center of the same industry as Elon Musk’s Neuralink and where players like Medtronic and Boston Scientific have been actively engaged in acquisitions. $ 100 b EP Market Opportunity 50 + Years of Combined Experience 100 + Over 100 Patents Issued or Pe
Slide 18: Potential Exit Opportunity
Potential Exit Opportunity Early Exit Opportunities All Potential Partners Multiple Large Players Robust M&A Environment Target Transaction Focus Stage $925 Million $575 Million $761 Million Ser A $425 Million $205 Million Ser C Undisclosed (1/22) (6/22) (1/22) (10/22) (1/22) (7/18) A - Fib Ablation
Slide 19: Financial Snapshot
Financial Snapshot Nasdaq: AMIX 19 $11.2 Million Initial Public Offering Closed January 26, 2024 $ 84 M 112 K 18.6 M Market Cap 1 Average Volume 1 Shares Outstanding 2 1: As of February 26, 2024 with a closing price of $4.53 2: As of January 26, 2024
Slide 20: Timeline
Timeline 2024 Sensing Technology Development Sensing Safety in Animals Animal Safety Testing Human Clinical Ablation Device Development POC - First in Human Clinical Trial - Pancreatic Cancer Pain Combined Sensing / Ablation Clinical Trial 2025 Ablation System and Catheter Ready for Human Pivotal Co
Slide 21: Proven Team with Multiple Successful Exits
Proven Team with Multiple Successful Exits EXECUTIVE CHAIRMAN CHIEF EXECUTIVE OFFICER CO - FOUNDER, CMO CO - FOUNDER, CTO CHIEF FINANCIAL OFFICER Wally Klemp Lori Bisson Dr. Robert Schwartz Landy Toth Trent Smith 21 Acquisition $550 Million Acquisition >$1 Billion Annual Revenue • Med device exit to
Slide 22: Investment Summary
22 Unleashing the Power of Nerve - Targeted Treatments Investment Summary Targeting Total Combined $100 Billion Market Opportunity Transforming the diagnosis and treatment of pain and diseases of the nervous system Ongoing human clinical trial with multiple near - term milestones Proven Team with Mu
Slide 23: Company Investor / Media Relations
Company Investor / Media Relations Autonomix Medical, Inc. 21 Waterway Ave, Suite 300 The Woodlands, TX 77380 833 - 475 - 8247 autonomix@jtcir.com autonomix.com
Autonomix Medical — Investor Presentation (March 2024) on 6ix